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ABSTRACT The b-adrenergic receptor kinase 1
(bARK1) is a member of the G protein-coupled receptor
kinase (GRK) family that mediates the agonist-dependent
phosphorylation and desensitization of G protein-coupled
receptors. We have cloned and disrupted the bARK1 gene in
mice by homologous recombination. No homozygote
bARK12/2 embryos survive beyond gestational day 15.5. Prior
to gestational day 15.5, bARK12/2 embryos display pro-
nounced hypoplasia of the ventricular myocardium essentially
identical to the ‘‘thin myocardium syndrome’’ observed upon
gene inactivation of several transcription factors (RXRa,
N-myc, TEF-1, WT-1). Lethality in bARK12/2 embryos is
likely due to heart failure as they exhibit a >70% decrease in
cardiac ejection fraction determined by direct in utero intra-
vital microscopy. These results along with the virtual absence
of endogenous GRK activity in bARK12/2 embryos demon-
strate that bARK1 appears to be the predominant GRK in
early embryogenesis and that it plays a fundamental role in
cardiac development.
G protein-coupled receptors are regulated by multiple mech-
anisms that serve to adapt their signaling ability to a constantly
changing environment. One of the most rapid mechanisms
modulating agonist-activated receptors is phosphorylation by
G protein-coupled receptor kinases (GRKs) resulting in the
uncoupling of the G protein-mediated transduction process
(1). This phenomenon, termed desensitization, affects both
sensory and hormonally responsive systems. Six distinct GRKs
(GRK1-6) have been identified to date. GRK1 or rhodopsin
kinase, and GRK2 or b-adrenergic receptor kinase 1
(bARK1), are the best studied members of the family (1, 2).
Phosphorylation of G protein-coupled receptors by GRKs
increases the receptor affinity for cytosolic proteins named
arrestins, which mediate uncoupling of the receptor from G
proteins, leading to transient desensitization (3) followed in
time by recovery of responsiveness (4).
Because of the lack of GRK selective drugs, the physiolog-
ical function of bARK1 is still largely unknown. With the
exception of the visual system in rodents and fly, where
rhodopsin kinase and arrestins have been implicated in the
quenching of the light reaction (5, 6), relatively little is known
about the role and function of GRKs in vivo. Initial insights
into the potential in vivo function of mammalian bARK1 have
recently come from investigating the potential role of bARK1
activity in the heart where b-adrenergic receptors regulate
cardiac chronotropy and inotropy (7). Transgenic mice over-
expressing either bARK1 or a peptide inhibitor of bARK1 in
the heart demonstrated that the activity of this kinase signif-
icantly contributes to the regulation of myocardial contractility
(8).
To gain further insights into the role of bARK1 in vivo, and
to determine its physiological involvement in the regulation of
G protein-coupled receptor function, we have disrupted the
bARK1 gene in mice. Our results reveal the unexpected
finding that bARK1 is required for embryonic cardiac devel-
opment and function and suggest a possible convergence
between G protein-coupled receptor signal transduction and
transcription factor pathways with respect to cardiac develop-
ment.
MATERIALS AND METHODS
bARK1 Gene Inactivation Procedure. For construction of
the targeting vector and production of chimeric mice, a 5.4-kb
HindIII–EcoRI fragment comprising exons 9–21 of the
bARK1 gene was subcloned in HindIII–EcoRI of pGEM4Z
(Promega) to generate plasmid pBK2-8HE. This plasmid was
linearized with HindIII, and an adapter (NotI, XbaI, EcoRI,
SalI, HindIII) was inserted to produce pBK2-8AHE. The
neomycin resistance cassette was excised by XhoI and EcoRI
from the plasmid pD383 (gift from R. Hen, Columbia Uni-
versity, New York), where this gene is under the control of the
human phosphoglycerate kinase promoter, followed by the
phosphoglycerate kinase poly(A1) signal. An 1822-bp frag-
ment was amplified by PCR between a primer 39 of exon 4
(CACATGAATTCACACCCCACAGGACTCTTAC,
EcoRI) and a primer 39 of exon 2 (GCTCAGTCTAGAGG-
GAAAACTTGGGGTG, XbaI). This XbaI–EcoRI fragment
was directionally subcloned, with the Neo cassette, in pBK2-
8AHE digested by XbaI and SalI, to generate the targeting
plasmid pBK-EHA14yNeo. Before electroporation of embry-
onic stem cells, pBK-EHA14yNeo was linearized by NotI.
Electroporation of embryonic stem cells, cell culture condi-
tions, G418 selection, DNA preparation, and generation of
chimeric mice were as described (9). Following transfection of
the targeting construct in embryonic stem cells, 108 clones
were tested by Southern blotting after digestion with either
EcoRI or XbaI. Five clones were found positive for one event
of homologous recombination. Two clones were further karyo-
typed and used for blastocyst injections. Numerous chimeric
males derived from EP-127.17 and EP-127.23 tested positive
for germ-line transmission. The results presented here corre-
spond to the germ-line EP-127.23.
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Southern Blot Procedure. Southern blots were performed as
described (9). Probe A was a 1.1-kb cDNA obtained by PCR
amplification in the intron located 59 of exon 2 using the primer
pair 59-CAGGTTGGCAGGTCTAGGG and 59-TCTACA-
GAGGGAGTTCCAGG. DNA was isolated from the tail of
adults and from tail and limbs of embryos following an
overnight digestion with proteinase K. Samples of DNA were
digested with excess of EcoRI, electrophoresed through 0.8%
agarose gels, and transferred to nitrocellulose membranes
prior to hybridization. Filters were washed at decreasing
concentrations of SSC with the final wash being in 0.13
SSCy0.1% SDS at 658C and exposed to X-R Kodak film for 48
hr.
Analysis of Embryos. For developmental studies bARK11/2
females were put in the presence of bARK11/2 males for 3 hr
and were checked for plugs. Positively plugged females were
considered at that point at gestational day 0 (E0). Embryos
were dissected at various time points (E7.5 on) and genotyped
as above. For Northern blot studies, the rest of the embryo was
frozen in dry ice and kept at 2808C until further use. For
histological procedures, embryos were put in formalin for at
least 24 hr, then embedded in paraffin, sectioned at 5 mm, and
stained with hematoxylin and eosin following standard pro-
cedures.
Gene Expression Studies. RNA from E13 embryos (ob-
tained from bARK1 heterozygous crossings) was extracted
and poly(A)1RNAwas isolated using oligo-d(T) (Amersham).
Poly(A)1 RNA (20 mg), originating from embryos of each
genotype, was run on a 1.2% agarose gel and transferred to a
nylon membrane as described (10). For protein immunoblot-
ting, embryonic or myocardial extracts were prepared as
described (8). Equal amounts of protein were then electro-
phoresed on SDSy12% polyacrylamide gels and transferred to
nitrocellulose. bARK1 was then identified by standard West-
ern blotting techniques using polyclonal antisera raised to the
carboxyl terminus of bARK1 and chemiluminescent detection
as described (8).
Assessment of GRK Activity. Concentrated supernatants
from adult heart and whole embryo extracts were used to
phosphorylate rhodopsin-enriched bovine rod outer segment
membranes as described (8). Extracts (50 mg protein) were
incubated in 75 ml with rod outer segment membranes in lysis
buffer with 10 mM MgCl2 and 0.1 mM ATP (containing
[g-32P]ATP). Purified Gbg was added to some samples for
maximal activity of bARK1. After incubation in white light for
15 min, the reactions were quenched with 300 ml of cold lysis
buffer and centrifuged for 15 min at 13,000 3 g. The sedi-
mented protein was then resuspended in 20 ml of lysis buffery
protein dye and electrophoresed on SDSy12% polyacrylamide
gels. Phosphorylated rhodopsin was quantified on a Molecular
Dynamics PhosphorImager.
Determination of Cardiac Ejection Fraction in Embryos.At
E12.5–13.5 pregnant mice were anesthetized with ketamine
(100 mgykg i.p.) and xylazine (2.5 mgykg i.p.) and were
intubated and ventilated as described (11, 12). Embryos were
visualized by intravital microscopy as described (13) with the
exception that real images obtained with a color CCD camera
were analyzed instead of fluorescent images. End-diastolic and
end-systolic frames defined as the largest and the smallest
images during the cardiac cycle were digitized and analyzed.
The area and the long axis of each left ventricle (LV) image
were measured with National Institutes of Health IMAGE
software. The border of each blood pool image was traced
three times and averaged using the single-plane area-length
method (14). End-diastolic and end-systolic LV volumes were
calculated using the following equation V 5 (8y3)(1/p)(1/
L)(A)2, where V is LV volume, A is the traced LV area, and
L is the long axis measured directly from the digitized video
image. The LV ejection fraction was calculated from the left
ventricular end-diastolic (LVEDV) and end-systolic volume
(LVESV) as (LVEDV 2 LVESV)yLVEDV.
RESULTS
bARK1Gene Disruption Is Lethal at Early Gestational Age.
The catalytic subdomain I, which forms part of the ATP
binding site, is encoded by exon 8. This exon was removed,
together with exons 5, 6, and 7, in the targeting vector for the
gene inactivation procedure to ensure that the resulting con-
struct did not confer any enzymatic activity (Fig. 1). Further-
more, the deletion altered the remaining reading frame. A
Southern blot of EcoRI-digested genomic DNA extracted
from tails of 3-week old litters, which were obtained by crossing
of bARK1 heterozygotes, is shown in Fig. 2 Upper. Wild-type
DNA gives a band at 25 kb, whereas the mutant genotype gives
a band at 17.5 kb as schematically represented in Fig. 1. None
of the 623 offspring examined from these crossings resulted in
bARK12/2 genotype indicating that the homozygotes die
during gestation (Table 1). The ratio of adult heterozygotes to
wild type is 2:1 and is consistent with Mendelian segregation
when homozygotes are lethal and heterozygotes are viable
(Table 1). bARK11/2 mice appear normal with no difference
in body weight or size at all ages examined (from birth until 9
weeks of age) (data not shown). Embryos from E7.5 to birth
were genotyped (Fig. 2 Lower, Table 1). At E7.5 very little
resorption is observed. Necrotic bARK12/2 embryos are
found from E9 on, suggesting that the lethality of bARK12/2
embryos begins at this time. Of the viable embryos, the
proportion of bARK12/2 embryos is roughly 25% at mid-
gestation days and decreases progressively up to E15.5 (Table
FIG. 1. Targeted disruption of the bARK1 gene. (Top) bARK1
cDNA and location of the 21 exons. Screening of a mouse sv129
genomic library (gift from H. S. Kim, University of North Carolina,
Chapel Hill) with two probes obtained from either rat bARK1 or
bARK2 cDNAs identified six clones of 12–15 kb. These clones were
overlapping as evidenced by restriction analysis and Southern blotting
(data not shown) and reconstituted a 23-kb DNA fragment. Exons 5–8
(solid boxes) were removed in the final construct for the gene
inactivation. Exon 8 contains the consensus catalytic subdomain I of
the protein kinases (15). The Gly and Val residues, in boldface type
and underlined, are known to bind ATP. (Middle) Physical map of the
bARK1 gene in the wild-type mouse. The thin line represents the
introns in the genomic DNA, and solid boxes represent the exons.
Intron 1 (.9 kb) is interrupted, as its actual size was not determined.
The EcoRI restriction fragment length is determined on the basis of
agarose gel electrophoresis and Southern blotting using the denoted
probe. (Bottom) Physical map of the bARK1 gene in mouse disrupted
by homologous recombination. The thick line represents the extent of
the targeting construct. The counterpart of the inserted neo resistance
DNA cassette is indicated by a shaded box. Solid boxes denote the
exons, and an additional EcoRI site generating a 17.5-kb restriction
fragment is represented.
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1). Following that gestational time, no viable bARK12/2
embryos are ever observed.
bARK1 Is the Major Kinase During Development. To
demonstrate that the embryonic lethality is associated with a
lack of functional bARK1 and that the disruption of the
bARK1 gene does indeed produce the expected functional
ablation of the enzyme, biochemical characterization including
Northern and Western blots, as well as GRK activity mea-
surements were performed on E11-E13 embryos (Fig. 3).
Northern blot analysis shows that bARK1 mRNA is expressed
very early during development and that this expression is very
low since analysis had to be performed on 20 mg of poly(A)1
RNA with prolonged exposure of the blots. Two bands are
obtained for the bARK1 transcripts from both wild-type adult
and embryo specimens as previously described for extracts of
adult bovine (15) or human tissues (16) (Fig. 3a). bARK11/2
embryos show a hybridization signal of markedly reduced
intensity (62% decrease). No signal is obtained in bARK12/2
embryos (Fig. 3a). The pattern of protein expression for
bARK1 correlates well with mRNA levels in each genotype,
i.e., early embryonic expression of a protein of the expected 80
kDa size, reduced expression in the bARK11/2 embryos, and
no signal in the bARK12/2 littermates (Fig. 3b).
To determine the GRK activity in relation to the embryo’s
genotype, we assessed whole embryo extracts for the ability to
phosphorylate light-activated rhodopsin, a prototypic G pro-
tein-coupled receptor and an in vitro substrate for bARK1 (8).
G protein bg subunits were also added to the reaction to
achieve maximum levels of rhodopsin phosphorylation. bg
subunits of heterotrimeric G proteins target bARK1 to the
membrane, which presumably facilitates the precise orches-
tration of bARK1 phosphorylation of only activated receptors.
Under the conditions of our experiments, most GRKs can
phosphorylate rhodopsin. Extracts from wild-type embryos
show a significant level of rhodopsin phosphorylation, which is
increased upon addition of the bg subunits. Extracts from
heterozygote embryos show lower levels of activity, which
correlate with the decrease in bARK1 mRNA and protein. In
contrast to wild-type animals, extracts from E13 homozygote
embryos are virtually devoid of activity (Fig. 3c). Even in the
presence of bg subunits, only a faint rhodopsin phosphoryla-
tion signal (,1%) is observed. Although we cannot exclude the
possibility that other GRKs are expressed at very low levels,
Western blots of early embryonic extracts reveal no detectable
protein expression of other prominent members of the GRK
family such as GRK3 (bARK2) and GRK5 (data not shown).
This is consistent with the idea that no other GRK is expressed
at levels high enough to produce either significant rhodopsin
phosphorylation or compensate for bARK1 gene disruption in
early development.
bARK12/2 Embryos Show Myocardial Hypoplasia. Ana-
tomical examination of bARK12/2 embryos reveals that they
are significantly smaller in size, with an overall development
retarded by approximately 24–36 hr at E15.5 in comparison to
wild-type littermates. They have a generally paler appearance
than their littermate controls and heterozygotes. This is sug-
gestive of insufficient vascular irrigation and not of a hema-
topoietic deficiency since the liver appears normal. Obvious
Table 1. Genotypic characterization of offspring from the bARK1 gene disruption
Offspring Measurement Homozygous Heterozygous Wild type Total
E9–E15.5 No. of offspring 39 85 48 172
% actual 23 49 25 100
(% theoretical) (25) (50) (25) (100)
E16–E20 No. of offspring 0 39 18 57
% actual 0 70 30 100
(% theoretical) (0) (67) (33) (100)
Postnatal No. of offspring 0 402 221 623
% actual 0 64 36 100
(% theoretical) (0) (67) (33) (100)
Heterozygote mice were crossed and the offspring’s genotype was analyzed during ontogeny and after
birth as described in Materials and Methods. E, gestational day.
FIG. 2. Southern blot analysis of EcoRI-digested genomic DNA
following the crossing of male and female heterozygote mice. DNA
was extracted from (Upper) tails of 3-week-old littermates or (Lower)
tails and limbs of littermate embryos at E13. Blots were hybridized
with a 59 f lanking probe. Wild-type and mutant allele correspond to
25 and 17.5 kb fragments, respectively.
FIG. 3. Biochemical characterization of the effects of bARK1 gene
disruption on extracts from E13 embryos obtained after crossing of
heterozygote mice. (a) Northern blot studies on 20 mg of poly(A)1
RNA extracted from whole E13 embryos hybridized with a cDNA
probe for bARK1 (Upper) or glyceraldehyde-3-phosphate dehydroge-
nase (Lower) used as control. (b) Western blot analysis using a rabbit
polyclonal antiserum to the COOH terminus of bARK1 (8). Chemi-
luminescent detection of alkaline phosphatase-conjugated secondary
antibody was used. (c) Assessment of GRK activity against rhodopsin
(see Materials and Methods).
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cardiac abnormalities in bARK12/2 embryos are found from
E11 on. Examination of dissected hearts at E13 reveals that the
right atrium of bARK12/2 embryos is significantly enlarged as
compared with littermate controls (data not shown). Histo-
logical sections of stained paraffin-embedded embryos reveal
striking abnormalities in the myocardium of the bARK12/2
embryos, which are reminiscent of the ‘‘thin myocardium
syndrome’’ observed with the targeted inactivation of several
transcription factors in the mouse (18) (Fig. 4). Hypoplasia of
both the right and left ventricular myocardium is apparent,
with notable hypoplasia in the right and left atria, and remark-
able hypoplasia and dysplasia of the interventricular septum.
In some of the embryos, the nontrabeculated ventricular
myocardium consists of only a single cell layer as shown in Fig.
4. The ventricular and atrial cavities (lumina) appear unusually
large as a consequence of the hypoplasia. There is persistence
of a wide interventricular foramen in the bARK12/2 embryos.
The interventricular foramen normally persists in the mouse
embryo until E14–E15 when the interventricular septum fuses
with the conotruncal ridges, dividing the right and left ven-
tricles (19). The persistence of an unusually wide interventric-
ular canal in the bARK12/2 embryos might be attributable to
its retarded growth. However, the dysplasia and hypoplasia of
the myocardium do not reflect the condition of a younger
heart, but represent a true and profound dysmorphogenesis.
This is evidenced by the abnormally thin compact myocardial
layer, the numerous and thinned trabeculae, and the lack of
cellular density where the muscular interventricular septum
should be forming. The endocardial and epicardial layers
appear normal. Slight variation in the extent or severity of the
defect are observed among embryos at different gestational
stages. This observation may be the consequence of the lack of
animals of pure genetic background and account for the
variation in the time of death of the embryos (E9.5–E15.5)
(20).
The reduced thickness of the compact layer of the myocar-
dium and the unusually thinned trabeculae in the ventricles
and atria of bARK12/2 embryos suggest a role for bARK1 in
the normal migration, differentiation, or proliferation of myo-
cardial cells from splanchnic mesoderm (originating in the
precardiac mesoderm). However, the normal morphology of
the endocardial cushions and epicardium (also derived from
FIG. 4. Cardiac abnormalities in bARK1 homozygote embryos visualized with hematoxylin- and eosin-stained sections of whole embryos. Two
sections each are shown at the aortic valve and left atrioventricular canal level. Structures are labeled as follows: B, bronchi; DA, descending aorta;
EC, endocardial cushion; IVF, interventricular foramen; IVS, interventricular septum; JRDA, junction of the right dorsal aorta; LA, left atrium;
LAVC, left atrioventricular canal; LV, left ventricle; RA, right atrium; RV, right ventricle; T, trachea.
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splanchnic mesoderm of the precardiac region) suggests that it
is only the sub-population of the precardiac mesoderm giving
rise to the compact myocardium and trabeculated myocardium
that are, directly or indirectly, dependent upon bARK1 gene
expression. Moreover, the normal appearance of cardiac struc-
tures containing neural crest cells (conotruncus, aortic sac, and
great vessels of the heart) in the bARK12/2 embryos suggests
that the bARK1 gene is not essential for normal migration of
the neural crest into the walls of the aortico-pulmonary
outflow tract (18).
bARK12/2 Embryos Die from Heart Failure. Analysis on
E12.5–E13.5 embryos demonstrates significant impairment in
heart function of homozygote embryos in comparison to
littermate wild-type embryos, which correlates closely with the
histological findings. Intravital microscopy in utero with direct
visualization of intracardiac blood pools reveals a marked
decrease in the cardiac ejection fraction of homozygote em-
bryos, suggesting heart failure as a probable cause of lethality.
Indeed, whereas the calculated LV ejection fraction in wild-
type hearts (n5 6) averages 56%, that of bARK12/2 embryos
(n 5 5) is 16%, with some of them having an ejection fraction
as low as 9% (Fig. 5). These results provide direct evidence that
the thin myocardium syndrome observed in these animals
results in ventricular chamber dysfunction of a magnitude
sufficient to cause embryonic heart failure. Interestingly, a
similar impairment in cardiac function has recently been shown
in mice carrying a similar morphological syndrome due to
inactivation of the RXRa gene for retinoic acid (21).
DISCUSSION
In this work, we describe the characteristics of the genetic
disruption of the mouse bARK1 (GRK2) gene, a member of
the GRK family. Our data strongly suggest that (i) bARK1
appears to be the major contributor to the GRK activity
present at this stage of development, (ii) that it is crucial during
embryogenesis, and (iii) that it plays a key role in cardiac
development and function as evidenced by the appearance of
a thin myocardium syndrome, cardiac pump failure, and fetal
death of bARK12/2 embryos. Thus, our results point to
bARK1 as an essential protein during development such that
no other GRK can compensate for its loss.
The finding that bARK1 disruption dramatically impairs
cardiac development and function during early embryogenesis
despite low levels of expression of the corresponding mRNA
in normal adult heart (data not shown) and whole embryos
(Fig. 3a) is unexpected. bARK12/2 embryos exhibit a pro-
nounced hypoplasia of the ventricular myocardium and an
obvious lack of organization or differentiation of the ventric-
ular myocardium. This phenotype is observed between E12.5–
E15.5 when one major cause of embryonic lethality can be
inefficient pumping action of the heart leading to circulatory
failure. Indeed, the LV ejection fraction of homozygote em-
bryos measured in utero is 29% that of wild-type littermates.
This strongly suggests that homozygote embryos are dying
from heart failure as a consequence of an abnormally thin
compact layer and disorganized trabeculae in the ventricular
wall.
The proper functioning of the cardiovascular system is a
prerequisite for embryonic survival. A large portion of pre-
term abortions can presumably be accounted for by congenital
circulatory system abnormalities (18). Consequently, under-
standing the mechanisms and factors involved in cardiogenesis
is of critical importance. Cardiac specific expression of genes
occurs between E8 and E16 (22). This correlates with the
differentiation, regionalization, septation, and growth of the
developing heart. Cardiac cell proliferation and differentiation
is also controlled in part by paracrine and autocrine mecha-
nisms including hormones and growth factors such as norepi-
nephrine, endothelin-1, and angiotensin, which activate G
protein-coupled receptors (23, 24). Through G protein-
coupled receptor dependent mechanisms catecholamines con-
trol chronotropy and inotropy in the normally functioning
heart. Evidence suggests that the regulation of these signaling
events through GRKs plays a critical role in the response to
adrenergic agents and may be modified in heart failure (25).
Thus, the essential role of bARK1 in cardiogenesis suggests
that it may represent a candidate gene susceptible to congen-
ital mutations, which lead to fetal death.
Interestingly, inactivation of the bARK1 gene leads to
precisely the same cardiac developmental defects that are seen
with inactivation of several transcription factor genes such as
RXRa (26, 27), N-myc (28), TEF-1 (29), and WT-1 (30). This
suggests that, during development, these transcription factors
or processes under their control may be regulated by as yet
unidentified G protein-coupled receptor signaling pathways,
the function of which is distorted by the absence of the bARK1
regulatory system. It is known, for example, that G protein-
coupled receptors modulate the activity of several transcrip-
tion factors via p21ras-dependent and -independent signaling
and MAP kinase cascades (31). Second messengers such as
cAMP, the levels of which are regulated by G protein-coupled
receptors, are also known to regulate several transcription
factor pathways (31). Moreover, it has been shown in neonatal
cardiomyocytes that retinoic acid inhibits G protein-coupled
receptor-mediated endothelin and a-adrenergic signals lead-
ing to cardiac hypertrophy (32). Therefore, it is conceivable
that during embryonic development the same or different
signals mediated through G protein-coupled receptors and
affected by retinoic acid might serve to program maturation of
ventricular myocytes. Alternatively, the effects of bARK1
gene disruption may result from the interaction of GRKs with
components of other cellular processes. The identification of
a potential convergence between G protein-coupled receptor
signaling and transcription factors in cardiac development may
provide an important framework for the characterization of
the signals and determinants of cardiogenesis. In summary, the
results presented here suggest that bARK1 (GRK2) plays a
fundamental role during development and thus participates in
intracellular signal transduction mechanisms, which regulate
cardiogenesis.
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